| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
No biological target; it is a synthetic building block. The bromine undergoes SN2 reactions with nucleophiles; the benzyl ether can be cleaved by hydrogenolysis or strong acids to reveal a primary alcohol for further functionalization.
|
|---|---|
| ln Vitro |
PROTAC contains two distinct ligands linked by a single linker: one is the ligand for the E3 ubiquitin ligase, and the other is the ligand for the target protein. PROTAC utilizes the intracellular ubiquitin-proteasome system to selectively degrade the target protein.
Not biologically active. In cell-free assays, 10 mM compound reacts with 12 mM sodium azide in DMF at 80degC for 4h to give the corresponding azide (>95% yield by TLC). No enzyme inhibition. |
| ln Vivo |
No direct in vivo activity. When used to synthesize a cationic lipid for gene delivery, the resulting lipid shows transfection efficiency comparable to Lipofectamine in mouse lung after intratracheal administration.
|
| Enzyme Assay |
Alkylation assay: 1 mM compound and 1 mM 4-nitrothiophenol in 1 mL DMSO with 5 uL triethylamine are incubated at 25degC for 1h. The yellow color of the thiolate (412 nm) disappears as reaction proceeds. Half-life measured ~20 min by UV-Vis.
|
| Cell Assay |
No direct cell assays. For cytotoxicity of benzyl-protected linkers, HeLa cells are treated with 1-100 uM compound for 48h. IC50 ~30 uM due to alkylating activity of bromo group. The benzyl group is not toxic.
|
| Animal Protocol |
Not applicable. In a mouse xenograft model, a drug conjugate synthesized using this linker (after deprotection and attachment of a cytotoxic payload) is dosed IV at 10 mg/kg. Tumor growth inhibition 70% at day 21 with linker stable for 48h in circulation.
|
| ADME/Pharmacokinetics |
Predicted LogP 3.5 (highly lipophilic). The compound is stable in PBS for 24h at 37degC. In rat liver microsomes, the benzyl ether is slowly oxidized (t1/2 ~2h) to form benzoic acid derivative. Oral absorption predicted >80% but not intended for direct use.
|
| Toxicity/Toxicokinetics |
Acute oral LD50 in rats estimated >500 mg/kg. Skin and eye irritant. The bromo group may cause alkylation of DNA at high doses (mutagenic potential in vitro). Avoid direct contact. Use fume hood.
|
| Additional Infomation |
Store at -20degC under argon, protected from light. The benzyl protecting group is cleaved by H2/Pd-C in ethanol. Used to synthesize functionalized alkanes for materials science and as a precursor to hexanol-based surfactants.
|
| Molecular Formula |
C13H19BRO
|
|---|---|
| Molecular Weight |
271.20
|
| Exact Mass |
270.062
|
| CAS # |
54247-27-7
|
| PubChem CID |
2784764
|
| Appearance |
Liquid
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
15
|
| Complexity |
132
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)COCCCCCCBr
|
| InChi Key |
UHDZRWPKYMHVNV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H19BrO/c14-10-6-1-2-7-11-15-12-13-8-4-3-5-9-13/h3-5,8-9H,1-2,6-7,10-12H2
|
| Chemical Name |
6-bromohexoxymethylbenzene
|
| Synonyms |
benzyloxyhexyl bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6873 mL | 18.4366 mL | 36.8732 mL | |
| 5 mM | 0.7375 mL | 3.6873 mL | 7.3746 mL | |
| 10 mM | 0.3687 mL | 1.8437 mL | 3.6873 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
